TI
PSTX

Trexquant Investment’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Trexquant Investment’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-146,487
Closed -$451K – 1883
2023
Q1 		$451K Buy
146,487
+113,233
+341% +$679K 0.01% 1048
2022
Q4 		$176K Buy
+33,254
New +$152K 0.01% 1265
2021
Q4 		– Sell
-12,442
Closed -$91K – 1699
2021
Q3 		$91K Buy
+12,442
New +$107K 0.01% 1058

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Trexquant Investment's PSTX Position: Q2 2023 in Review

Trexquant Investment sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q2 2023, closing a stake of 146,487 shares — an estimated $451K sold.

Trexquant Investment first reported a position in PSTX in Q3 2021 and held it in 3 quarters. The position peaked at $451K in Q1 2023. 94 funds tracked by Wall St. Rank hold PSTX as of Q2 2023.

  • Trexquant Investment reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Trexquant Investment sold 146,487 Poseida Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $451K.
  • Trexquant Investment first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2021 and held it in 3 quarters.
  • Trexquant Investment's Poseida Therapeutics, Inc. Common Stock position peaked at $451K in Q1 2023.
  • 94 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Trexquant Investment's 13F filing for Q2 2023, filed 11 Aug 2023.